Lv1
100 积分 2023-06-05 加入
Limertinib: First Approval
2小时前
待确认
Structural Perspectives in the Development of Novel EGFR Inhibitors forthe Treatment of NSCLC
4小时前
已完结
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
4小时前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
7天前
已完结
Rational combinations of targeted cancer therapies: background, advances and challenges
8天前
已完结
Tumour heterogeneity and resistance to cancer therapies
8天前
已完结
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
8天前
已完结
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
8天前
已完结
Inflammation and immune biomarkers: new frontiers in understanding and managing diabetes complications
8天前
已完结
Epidemiology of Spondyloarthritis in the People’s Republic of China: Review of the Literature and Commentary
10天前
已完结
皖公网安备34019202002308
